

Rivaroxaban for treatment and/or prevention of recurrence of VTE/PE (excluding prevention of VTE after hip or knee replacement) – Initiation Checklist (primary care only)

For cautions, contra-indications and interactions refer to SPCs– [rivaroxaban 15mg](#) and [rivaroxaban 20mg](#)
[NICE TA 287](#) - Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
[NICE TA 261](#) - Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism

Refer to: [Wirral Oral Anticoagulant Guidelines](#)

Patient details:

Name: _____ DOB: _____
 Weight: _____ SrCr: _____

Creatinine Clearance Calculation (CrCl): Calculation of CrCl using Cockcroft and Gault equation** or a reputable online CrCl calculator.

$$\frac{(140 - \text{Age} \dots\dots\dots) \times \text{Weight}^* \dots\dots \times \text{CONSTANT} \dots\dots}{\text{Serum creatinine (micromol/L)} \dots\dots\dots} = \dots\dots \text{ ml/min}$$

CONSTANT
Male = 1.23
Female = 1.04

* Female use actual body weight if ≤ 60kg, if > 60kg use 60kg. Male use actual body weight if ≤ 70kg, if > 70kg use 70kg.

**Cockcroft and Gault does not apply to all patients. Exclusion criteria include: unstable serum creatinine, pregnancy, malnutrition, amputation and dialysis

Renal Function:

- Patient's CrCl is greater than 50mls/min (standard dose)
- Patient's CrCl is between 15-49mls/min (consideration of reduced dose)
- Patient's CrCl is less than 15mls/min (rivaroxaban contra-indicated)

Indication for rivaroxaban as per marketing authorisation (treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults) and [NICE TA261](#) and [NICE TA287](#)

Baseline checks to be undertaken – aPTT, INR, Hb, U&Es and LFTs

Consider contraindications, cautions and interacting drugs using references at the top of the page.

The recommended dose for the initial treatment of acute DVT or PE:

	Dosing schedule	Maximum daily dose
Day 1-21	15 mg twice daily	30 mg
Day 22 and onwards	20 mg once daily	20 mg

Reduced dose

1. **CrCl is between 15-49ml/min.** 15 mg twice daily for the first 3 weeks. Thereafter, the recommended dose is 20 mg once daily. A reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient's assessed risk for bleeding outweighs the risk for recurrent DVT and PE.

Duration of therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding. Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE.

Patient has been counselled, given a rivaroxaban alert card and [patient information leaflet](#)

Patient understands the risk/benefits of rivaroxaban, that therapy is long term and understands that there is currently no antidote for potential bleeding risk

Prescriber's Signature: _____

Date: _____

Wirral Medicines Management June 2017 v1.1

Written by Victoria Vincent. Checked by Rachael Pugh